Overview

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences